The quarter beat on earnings, with revenue essentially in line. Published estimates called for roughly $235.9 million of revenue and $0.36 of EPS; Daktronics delivered $234.6 million and $0.40, respectively, making the cleanest surprise an EPS beat rather than a top-line acceleration. 〔0〕
| Metric | Q1 FY2027 | Q1 FY2026 / expectation | Read |
|---|---|---|---|
| Net sales | $234.6M | $219.0M / ~$235.9M consensus | 7.1% YoY; roughly in line with expectations (Income Statement) |
| Diluted EPS | $0.40 | $0.33 / ~$0.36 consensus | Beat (Income Statement) |
| Operating income | $24.9M | $23.3M | 7.1% YoY (Income Statement) |
| Operating margin | 10.6% | 10.6% implied from reported figures | Held at a strong level (Financial Highlights) |
| New orders | $191.8M | $238.5M | Down 19.6% YoY (Orders table) |
| Product backlog | $311.3M | $360.3M | Down 13.6% YoY, though still above $300M (Financial Highlights) |
| Free cash flow | $27.5M | $22.0M | Improved (Free Cash Flow reconciliation) |
Margin and cash execution supplied the upside. Gross margin expanded to 30.5% from 29.7%, while operating income rose despite the current quarter having one fewer reporting week. Tariff refunds helped gross margin, so part of the improvement may not be fully repeatable. Operating cash flow increased to $31.4 million and free cash flow to $27.5 million.
The forward-demand signal is weaker than the headline EPS beat. Orders fell nearly 20% year over year and backlog declined by roughly $49 million. Management attributed the orders shortfall to several substantial transactions expected to book in Q2, which makes the result less alarming but leaves the explanation to be validated by actual bookings. The backlog remains substantial, but it no longer provides the same year-over-year growth cushion. 〔1〕
The balance sheet and capital actions add support, not a new catalyst. Cash reached $154.6 million against $10.5 million of total debt, and the company repurchased $4.4 million of stock. The new $34.5 million repurchase authorization is described as substantially equivalent to the remaining prior authorization, so it does not materially change capital allocation. The CEO's salary increase and the credit-agreement amendment are secondary disclosures with limited immediate earnings impact.
Net: a narrow beat, but not a clean demand victory. The EPS outperformance and better cash generation outweigh the roughly in-line revenue, while the orders and backlog decline keep the result from reading as a broad upside surprise. The next proof point is whether the deferred large transactions actually convert into Q2 orders and rebuild backlog.
Read the original 8-K on SEC EDGAR ↗